Inhibrx Inc (INBX)
34.31
+0.07
(+0.20%)
USD |
NASDAQ |
May 22, 14:22
Inhibrx Cash from Financing (Quarterly): 38.73M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 38.73M |
December 31, 2023 | 0.86M |
September 30, 2023 | 199.89M |
June 30, 2023 | 0.854M |
March 31, 2023 | 0.356M |
December 31, 2022 | 158.66M |
September 30, 2022 | 0.506M |
June 30, 2022 | 60.16M |
March 31, 2022 | 39.22M |
December 31, 2021 | 41.48M |
September 30, 2021 | 0.82M |
June 30, 2021 | 40.48M |
Date | Value |
---|---|
March 31, 2021 | 0.988M |
December 31, 2020 | 17.00M |
September 30, 2020 | 136.22M |
June 30, 2020 | 16.88M |
March 31, 2020 | -3.633M |
December 31, 2019 | -0.439M |
September 30, 2019 | -1.885M |
June 30, 2019 | 35.86M |
March 31, 2019 | 9.795M |
June 30, 2018 | 7.135M |
March 31, 2018 | -1.755M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.633M
Minimum
Mar 2020
199.89M
Maximum
Sep 2023
39.15M
Average
16.94M
Median
Cash from Financing (Quarterly) Benchmarks
Axonics Inc | 0.248M |
NovaBay Pharmaceuticals Inc | -0.597M |
Palatin Technologies Inc | 9.136M |
iBio Inc | 5.025M |
Theriva Biologics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -63.05M |
Cash from Investing (Quarterly) | -1.119M |
Free Cash Flow | -222.10M |
Free Cash Flow Per Share (Quarterly) | -1.176 |
Free Cash Flow Yield | -12.98% |